Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.

Leukemia - 1 Aug 2018

Xiao Wenbin, Rampal Raajit, Zhang Yanming, Cimera Robert, Jungbluth Achim A, Arcila Maria, Roshal Mikhail, Park David C

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cell Differentiation
Share to Erythroid Cells
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Leukemia, Myeloid, Acute

Share to Megakaryocytes

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 29743724
DOI: 10.1038/s41375-018-0145-6
PMCID: PMC7472720

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.PMID 29743724Read ↗

[Research advances in the role of JAK2 mutations in acute leukemia].Semantic proximity Read ↗

Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders.Semantic proximity Read ↗

BCR/ABL-negative chronic myeloproliferative disorders: JAK2 mutation and beyond.Semantic proximity Read ↗

Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapySemantic proximity Read ↗

JAK/STAT in leukemia: a clinical updateSemantic proximity Read ↗

Tyrosine kinase oncogenes in normal hematopoiesis and hematological diseaseSemantic proximity Read ↗

TP53 signal pathway confers potential therapy target in acute myeloid leukemia.Semantic proximity Read ↗

JAK2 mutation and atypical chronic myeloid leukemia.Semantic proximity Read ↗

Jak2: normal function and role in hematopoietic disorders.Semantic proximity Read ↗

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Semantic proximity Read ↗

BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation.Semantic proximity Read ↗

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.